Physician profile
Alexandra Jane Borst
NPI 1245542380
$27,295.51
in general payments reported to CMS, 2019-2025
7 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,381 · 2022: $36.80 · 2023: $967 · 2024: $5,625 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,563 · Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,562.50 |
| Food and Beverage | $176.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $15,062.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $6,745.55 | 2022-2025 | Vijoice |
| Novo Nordisk Health Care Ag | $2,720.00 | 2020 | |
| Novo Nordisk INC | $1,436.30 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $1,300.96 | 2020 | |
| Pfizer INC. | $16.43 | 2023 | |
| Exeltis, USA INC. | $13.49 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Borst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.